CCTV, Beijing, November 19 (Reporter Ma Kejia) The new crown vaccine prevention and the development of specific drugs are both important, or it may bring a new "turning point" for the global epidemic prevention and control to return to normal
DXP-604 was jointly developed by Peking University's Xie Xiaoliang team and Danxu Biotechnology.
"At the beginning of the epidemic, we had acquired antibodies since March and April last year.
Neutralizing antibody drugs are isolated from the serum of recovered patients with new coronary pneumonia, and target the new coronavirus spike protein receptor binding domain (RBD), which wraps the functional area of the cell invading the cell and prevents the virus from infecting the cell
It is reported that at present, three R&D teams in China are at the forefront of the world in terms of neutralizing antibody drugs
Zhong ASTRI ASTRI In November 2021, the phase II clinical trial of the antibody JS016 developed by Yan Jinghua's team was completed.
Zhong ASTRI ASTRI Zhong ASTRI ASTRI Professor Zhang Linqi of Tsinghua University cooperated with Shenzhen Third People's Hospital and Tengsheng Bo Yao
Xie Xiaoliang's team started clinical practice as sympathetic medication in Ditan Hospital
"Ditan Hospital is very standardized in the use of sympathetic medication, and DXP-604 is also effective
Focus on the new crown pneumonia epidemic
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
